Spravato, a ketamine nasal spray, is being subsidized for treatment-resistant depression. Learn about its benefits, usage, and eligibility criteria.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making it much cheaper for the e. Tuesday, 02 January 2024 12:17 GMT.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

After it was approved in 2019, Spravato, a depression treatment derived from the club drug ketamine, was looking like a dud. But recently it has taken off, and it surpassed $1 billion in annual ...

A nasal spray that uses a form of ketamine to treat stubborn depression will be added to the PBS, making treatment cheaper for thousands of Australians. It is the first new depression medication ...

Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market since 2019 , but could only be prescribed ...

A nasal spray derived from ketamine is being used to address treatment-resistant depression. The treatment will be more accessible for up to 30,000 Australians ...

Esketamine, a form of ketamine taken as a nasal spray, has been approved for the treatment for moderate to severe ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

A ketamine nasal spray will be subsidised for treatment-resistant depression. Here’s what you need to know about Spravato Nial Wheate, Macquarie University and Shoohb Alassadi, University of Sydney ...